* enrolled in another clinical trial for covid19. * rapidly progressive disease with anticipated life-expectancy \<72 hours. * patients requiring mechanical ventilation. * patients with multiorgan failure. * mild-moderate (grade ≥ 3) organ impairment (liver, kidney, respiratory), according to criteria from the national cancer institute (nci ctcae version 5.0). * severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol. * have a known history of human immunodeficiency virus infection, hepatitis b or hepatitis c; testing is not required in the absence of prior documentation or known history. * pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcg laboratory test. * any other condition that, in the opinion if the investigator, may interfere with the efficacy and/or safety evaluation of the trial.

* enrolled in another clinical trial for covid19. * rapidly progressive disease with anticipated life-expectancy \<72 hours. * patients requiring mechanical ventilation. * patients with multiorgan failure. * mild-moderate (grade ≥ 3) organ impairment (liver, kidney, respiratory), according to criteria from the national cancer institute (nci ctcae version 5.0). * severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol. * have a known history of human immunodeficiency virus infection, hepatitis b or hepatitis c; testing is not required in the absence of prior documentation or known history. * pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcg laboratory test. * any other condition that, in the opinion if the investigator, may interfere with the efficacy and/or safety evaluation of the trial.

- enrolled in another clinical trial for covid19. - rapidly progressive disease with anticipated life-expectancy <72 hours. - patients requiring mechanical ventilation. - patients with multiorgan failure. - mild-moderate (grade ≥ 3) organ impairment (liver, kidney, respiratory), according to criteria from the national cancer institute (nci ctcae version 5.0). - severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol. - have a known history of human immunodeficiency virus infection, hepatitis b or hepatitis c; testing is not required in the absence of prior documentation or known history. - pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcg laboratory test. - any other condition that, in the opinion if the investigator, may interfere with the efficacy and/or safety evaluation of the trial.

- enrolled in another clinical trial for covid19. - rapidly progressive disease with anticipated life-expectancy <72 hours. - patients requiring mechanical ventilation. - patients with multiorgan failure. - mild-moderate (grade ≥ 3) organ impairment (liver, kidney, respiratory), according to criteria from the national cancer institute (nci ctcae version 5.0). - severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol. - have a known history of human immunodeficiency virus infection, hepatitis b or hepatitis c; testing is not required in the absence of prior documentation or known history. - pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcg laboratory test. - any other condition that, in the opinion if the investigator, may interfere with the efficacy and/or safety evaluation of the trial.